*Range: 4 weeks to 4.5 years
ED, emergency department; ICS, inhaled corticosteroid; IL-5, interleukin-5; OCS, oral corticosteroid
Nucala is generally well tolerated. Very commonly or commonly reported adverse reactions in clinical trials included: headache; back pain; local injection site reactions; systemic administration-related and hypersensitivity reactions (which can occur after a long duration of treatment); LRTI; UTI; pharyngitis; nasal congestion; upper abdominal pain; eczema and pyrexia. 7
†MENSA was a 32-week exacerbation study comparing Nucala 100mg SC (n=194) vs placebo (n=191) in patients with severe eosinophilic asthma.
††SIRIUS was a 24-week glucocorticoid-sparing effect study comparing Nucala SC (100mg) with placebo added to SoC in 135 patients with severe eosinophilic asthma. 6
†††Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in a pre-filled pen, pre-filled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC regardless of weight and available in lyophilised powder. 7
The pre-filled formulations are not indicated in 6-11 year olds.
- Ortega H et al. N Engl J Med 2014; 371:1198–1207
- Chupp GL et al. Lancet Respir Med 2017; 5:390–400
- Lugogo N et al. Clin Ther 2016; 38:2058–2070
- Khurana S et al. Clin Ther 2019; 41 (10):2041-2056
- Khatri et al. 2019; J Allergy Clin Immunol; 143 (5): 1742-1751
- Bel EH et al. N Engl J Med 2014; 371:1189–1197
- Nucala Summary of Product Characteristics. Available at www.medicines.ie. Last Accessed December 2020
- http://www.ncpe.ie/drugs/mepolizumab-nucala/ Last accessed: December 2020